Andrew Potter
Andrew commenced his pharmaceutical career in 2011, working at 3 of the top 10 pharmaceutical companies in the world. Leaving mainstream pharma in January 2022, Andrew joined the market-leading medicinal cannabis company in Australia as a Medical Science Liaison. Throughout his pharma career, Andrew has launched four first-in-class therapies, treating osteoporosis, COPD, Asthma, and atrial fibrillation. Nowadays, his career is firmly anchored to medicinal cannabis. Andrew’s purpose is to help break down the stigma some healthcare professionals still hold against patients in need of safe, available, and cost-effective medicinal cannabis in Australia.
As an advocate for men’s mental health, Andrew raises money for charities specializing in care, treatment, and counseling, particularly aimed toward veterans.